Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
8 hedge funds and large institutions have $8.84M invested in Northwest Biotherapeutics, Inc. Common stock in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 48 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
52% less capital invested
Capital invested by funds: $18.3M → $8.84M (-$9.43M)
85% less funds holding
Funds holding: 54 → 8 (-46)
96% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 48
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $31K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$32.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.03M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$752K |
| 3 |
WIM
Woodford Investment Management
London,
United Kingdom
|
-$554K |
| 4 |
Goldman Sachs
New York
|
-$540K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$390K |
NWBO Hedge Fund Activity: Q4 2016 in Review
8 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q4 2016, worth a combined $8.84M — down 52% from $18.3M a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of NWBO and 2 opened new positions — a net loss of 46 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Brandes Investment Partners, opening a new position worth an estimated $32.7K. The largest seller was Credit Suisse, exiting entirely with an estimated $1.03M sold.
- 8 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q4 2016, down from 54 in Q3 2016.
- Funds reported $8.84M of Northwest Biotherapeutics, Inc. Common stock stock for Q4 2016, down 52% quarter-over-quarter.
- 2 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q4 2016 and 48 closed out, a net change of -46 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q4 2016 was Brandes Investment Partners, an estimated $32.7K added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q4 2016 was Credit Suisse, an estimated $1.03M sold.
Based on aggregated 13F filings for Q4 2016.